Sean Khozin, MD, MPH is a physician-scientist and oncologist, internationally recognized for his leadership in leveraging data science, AI, machine learning, and real-world evidence to drive innovation in biomedical research, with a particular emphasis on oncology drug development.
Currently, Dr. Khozin serves as the Chief Executive Officer of the CEO Roundtable on Cancer (CEORT) and Project Data Sphere (PDS). In these roles, he directs the organizations' public health programs in addition to pioneering initiatives focused on the development of AI foundation models in oncology. Concurrently, as the Founder of Phyusion and a Research Affiliate at the Massachusetts Institute of Technology (MIT), Dr. Khozin focuses on novel applications of AI and machine learning technologies to accelerate drug discovery and optimize therapeutic development strategies.
Previously, Dr. Khozin served as the Chief Executive Officer of CancerLinQ, where he led the restructuring and acquisition of the precision oncology enterprise leveraging real-world data and analytics. He also held the position of Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, implementing cutting-edge data science solutions to support the development of innovative medicines and vaccines.
Dr. Khozin's regulatory experience includes roles as a founding member of the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence and the inaugural Executive Director of FDA INFORMED, the agency's first data science incubator that he established under special federal authorities. In this capacity, he helped shape the FDA's stance on real-world evidence and adoption of data science methodologies across the product life cycle.
Earlier in his career, Dr. Khozin co-founded Hello Health, a technology company developing telemedicine, data visualization, and analytics solutions for optimizing patient care and clinical research. He also founded SKMD, a multidisciplinary clinical network. Dr. Khozin has over a decade of experience in clinical and basic science research at the National Cancer Institute, having started his clinical work developing novel molecular profiling strategies in thoracic malignancies.
Currently, Dr. Khozin serves as the Chief Executive Officer of the CEO Roundtable on Cancer (CEORT) and Project Data Sphere (PDS). In these roles, he directs the organizations' public health programs in addition to pioneering initiatives focused on the development of AI foundation models in oncology. Concurrently, as the Founder of Phyusion and a Research Affiliate at the Massachusetts Institute of Technology (MIT), Dr. Khozin focuses on novel applications of AI and machine learning technologies to accelerate drug discovery and optimize therapeutic development strategies.
Previously, Dr. Khozin served as the Chief Executive Officer of CancerLinQ, where he led the restructuring and acquisition of the precision oncology enterprise leveraging real-world data and analytics. He also held the position of Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, implementing cutting-edge data science solutions to support the development of innovative medicines and vaccines.
Dr. Khozin's regulatory experience includes roles as a founding member of the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence and the inaugural Executive Director of FDA INFORMED, the agency's first data science incubator that he established under special federal authorities. In this capacity, he helped shape the FDA's stance on real-world evidence and adoption of data science methodologies across the product life cycle.
Earlier in his career, Dr. Khozin co-founded Hello Health, a technology company developing telemedicine, data visualization, and analytics solutions for optimizing patient care and clinical research. He also founded SKMD, a multidisciplinary clinical network. Dr. Khozin has over a decade of experience in clinical and basic science research at the National Cancer Institute, having started his clinical work developing novel molecular profiling strategies in thoracic malignancies.